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Background: Since Highly Active Antiretroviral Therapy (HAART) medications were made available in 2002, multiple
serious side effects have been observed. However, no study has yet systematically evaluated the prevalence of liver
steatosis, a very serious but treatable side effect.
Objectives: This study examined the prevalence of and independent risk factors for liver steatosis in Chinese HIV-
infected, HAART-experienced patients who had been diagnosed with hypertriglyceridemia.
Methods: In this cross-sectional observational study, the prevalence of liver steatosis was determined by ultrasound
imaging that detected diffusion in hepatic echogenicity. The risk factors associated with steatosis were evaluated
with a proportional odds logistic regression model.
Results: Among 163 HIV-infected patients with hypertriglyceridemia and past HAART experience, 75(46%) patients
were determined to have liver steatosis. In multivariable logistic regression model, the risk factors associated with
liver steatosis were: higher triglyceride level (OR = 1.086, P = 0.026), metabolic syndromes (OR = 2.092, P = 0.024)
and exposure to nucleoside reverse transcriptase inhibitor (NRTIs) ((OR = 2.11, P = 0.001) and Stavudine (OR = 3.75,
P = 0.01)). Exposure to Nevirapine (OR = 0 .41, P = 0.003) was a favorable factor for lipid metabolism in vivo and was
a protective factors for liver steatosis.
Conclusions: Chinese HIV-infected patients with hypertriglyceridemia appear to be prone to liver steatosis,
especially those on NRTIs. Routine screening should be considered on their lipid panels.
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Liver steatosis has become the most common non-viral
hepatic disease worldwide [1]. In developed countries,
prevalence of nonalcoholic fatty liver disease(NAFLD)
fluctuates between 20-30% in the general population
[1,2]; in the U.S., it is between 17-33% [3-5]. Fan Jiangao
et al. [6] reported that the prevalence of liver steatosis
was 15% in Shanghai general population and gradually
increasing. Studies have shown that risk factors for liver
steatosis include obesity, dyslipidemia, diabetes, insulin
resistance and other factors.
Among the HIV-infected population, the widespread
use of HAART has reduced mortality and increased* Correspondence: zhao_hongxin66@yahoo.com.cn
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reproduction in any medium, provided the orsurvival rates of AIDS patients but has also brought with
its metabolic side effects, such as hyperlipidemia and
fatty liver (i.e. steatosis). Crum-Cianflone et al. [7]
reported that prevalence of NAFLD in HIV-infected
population in the U.S. Veterans Administration Health
System was 31% based on ultrasound imaging, with a
greater waist circumference, lowered high-density lipopro-
tein (HDL) and elevated triglyceride levels. Lesi et al. [8]
reported that 13.3% of Africans with HIV had elevated
low-density lipoprotein (LDL) levels.
In China, the pilot for the National Free HAART Pro-
gram began in Henan Province in 2002, and the program
fully began in 2003 [9]. The extent of liver steatosis has
yet to be determined. In the present study, we examined
the prevalence of and risk factors associated with liverd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline descriptive data for study centers in
Chinese HIV patients with hypertriglyceridemia
Baseline descriptive data Cases (%)
Study center (total 180 cases)
Ditan Hospital (north China) 42 (23.3%)
You’an Hospital (north China) 24 (13.3%)
Henan TCM Hospital (central China) 48 (26.7%)
Anhui TCM Hospital (central China) 18 (10.0%)
Guangzhou 8th Hospital (south China) 30 (16.7%)
Xiangya 2nd Hospital (south-central China) 18 (10.0%)
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with hypertriglyceridemia.
Methods
The study was received the approval of the Ethics Com-
mittee from following study sites: Ditan and You’an
Hospital in north China, Henan Traditional Chinese
medicine (TCM) Hospital and Anhui TCM Hospital in
central China, Guangzhou 8th Hospital in South China
and Xiangya Second Hospital in south-central China.
All of the participants meeting the inclusion criteria had
signed informed consent.
Procedures
We conducted a cross-sectional observational study.
According to guideline for prevention and treatment of
AIDS in China [10] and guideline for prevention and treat-
ment of hyperlipidemia in adults [11] recommended by
Chinese Medical Association, eligible participants in
HIV-infected patients with hypertriglyceridemia were:
(1) HIV-positive (confirmed by enzyme-linked immuno-
sorbent assay (ELISA) and Western Blot), (2) HAART
experienced, (3) and diagnosed with hypertriglyceridemia
(marginal increase (1.70-2.25 mmol/L) or an increase
(>2.26 mmol/L)) [11]. Patients with severe primary disease
of the heart, liver, kidney or hematopoietic systems, taking
lipid-lowering drugs, or who were pregnant or breast-
feeding were excluded. Patients were recruited and en-
rolled at Ditan and You’an Hospitals in north China,
Henan and Anhui Traditional Chinese Medicine (TCM)
Hospitals in central China, Guangzhou 8th Hospital in
south China, and Xiangya Second Hospital in south-
central China. This study was approved by Institutional
Review Boards at each hospital, and all enrolled partici-
pants provided written informed consent.
The study was conducted from January 2008 to June
2010 as part of a parent study on side effects treatment.
Across study sites, 180 participants were recruited and
scheduled for ultrasound imaging. As 17 did not appear for
the screening visit, data were available for 163 participants.
HIV/HCV co-infected patients and normal control
participants have also been enrolled as control groups in
this study. eligible participants in HIV/HCV co-infected
patients were: (1) HIV-positive, (2) HAART experienced,
(3) positive serum antibodies to HCV and detectable serum
HCV RNA. Exclusion criteria were: co-infection with
HBV, decompensated cirrhosis and other known causes of
liver disease. A total of 69 HIV/HCV co-infected patients
met these criteria. Another 30 participants were enrolled
as normal control.
Measures
Participants completed a face-to-face paper-and-pencil
questionnaire eliciting data on gender, age, ethnicity,smoking and drinking history (alcohol intake of more
than 20 g/day for men or 10 g/day for women), time since
HIV diagnosis, source of HIV transmission, time on
HAART, and current CD4 count. Study staffs recorded
participants’ height, weight, heart rate, blood pressure, and
body mass index (BMI) as obese (≥ 30 kg/m2), overweight
(25.0-29.9 kg/m2) and normal (18.6-24.9 kg/m2). Labora-
tory tests were performed for lipid panels as well as liver
and kidney function (see Table 1); fasting plasma glucose;
and current CD4 count. Metabolic syndrome was deter-
mined according to diagnostic criteria recommended by
the Chinese Medical Association [11], i.e., meeting three or
more of the following: BMI ≥ 25 kg/m2, serum triglyceride
(TG) ≥ 1.7 mmol/L, serum lower HDL (men ≤ 0.91 mmol/L,
women ≤1.04 mmol/L), blood pressure ≥140/90 mmHg,
fasting plasma glucose ≥6.1 mmol/L, and diabetes.
All participants underwent an ultrasound to detect
liver steatosis and hepatomegaly. Per Chinese Medical
Association recommendations [12], liver steatosis was
defined by ultrasound imaging indicating diffusion in
hepatic echogenicity.
Statistical analysis
All data were analyzed using SAS 9.1.3 (SAS Institute,
Cary, NC, USA). Continuous variables were expressed
by mean ± standard deviation and Analysis of Variance
was used for comparing quantitative variables among or
between normal control, HIV/HCV co-infection group
and HIV-infected patients with hypertriglyceridemia, re-
spectively. Categorical variables were expressed by per-
centages and chi-squared tests were used for statistical
comparisons of categorical variables. P < 0.05 was con-
sidered significant.
In HIV-infected patients with hypertriglyceridemia,
univariate logistic regression models were first used to
determine the association of the following variables with
the presence of liver steatosis: sex; age; drinking history;
time since HIV diagnosis; time on HAART; blood lipid
panels (total cholesterol, total triglycerides, HDL and LDL
levels); metabolic syndrome, liver and renal functions
(ALT, AST, T-BIL, D-BIL, BUN, creatinine); fasting plasma
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(BMI) is graded and has been shown for female vs male, a
chi-square test was firstly used to determine if BMI was
associated with the presence of liver steatosis. Statistically
significant predictors were included in a subsequent multi-
variate logistic regression model.
In HIV-infected patients with hypertriglyceridemia, a
chi-square test was used to determine if antiretroviral
medication was associated with the presence of liver
steatosis and then all medications were entered into a
multivariate logistic regression analysis to determine
their unique association with liver steatosis. Alpha was
set to 0.05, with 95% confidence intervals.
Results
Participant characteristics and baseline descriptive data in
HIV-infected patients with hypertriglyceridemia
In this study, 180 HIV-infected patients with hypertri-
glyceridemia and past HAART experience have been
recruited in several AIDS Treatment Centers in China
(Table 1). As 17 did not appear for the screening visit,
data were available for 163 participants.
See Tables 1 and 2 for a full description of 163 HIV-
infected patients with hypertriglyceridemia. As seen in
Table 2, mean age was 42.9 ± 9.3 years; 109 (66.9%)
were male. average time since HIV diagnosis and time
on HAART were 132 months (SD = 73 months) and
38.7 months (SD = 25.3 months), respectively. Mean
CD4 count was 316 cells/ul.
The study population was 100% Han Chinese (the
majority ethnic group). In 163 patients, 150 were taking
HAART and 13 had temporary discontinued ARV regi-
mens due to resistance. Participants had started on
first-line recommended HAART regimens [9] AZT/
d4T + 3TC +NVP/EFV; 17 (9.8%) had been on a second-
line HAART regimen, TDF + 3TC + LPV/r.
There was a marginal increase (5.18-6.19 mmol/L) or an
increase (>6.22 mmol/L) in total cholesterol levels in 39
(23.9%) and 45 (27.6%) participants, respectively; a marginal
increase (3.37-4.12 mmol/L) or increase (>4.14 mmol/L)
in LDL levels were detected in 24 (14.7%) and 14 (8.6%)
patients, respectively; 34 (20.9%) presented with lowered
HDL (<1.04 mmol/L). Biochemistry tests indicated that
liver and renal functions were normal results except
for a mild elevation of ALT (ALT > 40 U/L) found in 36
patients (22.6%).
Metabolic changes in HIV-infected patients with
hypertriglyceridemia: comparisons with HIV/HCV
Co-infected patients and normal control participants
Metabolic changes in this study was illustrated in
Table 3, showing that 3 groups of participants (HIV
with hypertriglyceridemia, HIV/HCV co-infection and
normal control) did not differ by age and percentage ofgenders. Cholesterol serum levels and prevalence of
hypercholesterolemia were significantly higher in HIV-
infected patients with hypertriglyceridemia than that
HIV/HCV co-infected patients and normal control par-
ticipants (p < 0.0001). We also found that HDL serum
levels were 1.2 ± 0.3 and 0.9 ± 0.4 mmol/L in patients
with hypertriglyceridemia and HIV/HCV co-infection,
which were significantly lower than that in normal con-
trol (p < 0.0001), and prevalence of lower HDL serum
levels was similar in patients with hypertriglyceridemia
and control participants (20.9% & 23.3%) but was
significantly higher in HIV/HCV co-infected patients.
Prevalence of metabolic syndrome was 47.9% in patients
with hypertriglyceridemia while it was 18.9% and 16.7% in
HIV/HCV co-infected patients and normal control, re-
spectively. We also found that, in HIV-infected patients
with hypertriglyceridemia, Prevalence of liver steatosis was
significantly higher than that in HIV/HCV co-infected
patients and normal control (p < 0.0001).
Prevalence and predictors of liver steatosis in HIV-infected
patients with hypertriglyceridemia
Liver steatosis was confirmed in 75 (46%) of the partici-
pants and 9 (5.5%) had hepatomegaly in this group. As
seen in Table 2, univariate models indicated that gender,
drinking history, triglyceride levels, high fasting plasma
glucose, metabolic syndrome, and CD4 count was asso-
ciated with liver steatosis. None of the other predictor
was significantly associated with liver steatosis. In the
multivariate analysis with these predictors, only total tri-
glyceride levels (OR = 1.086, P = 0.026) and metabolic
syndrome (OR = 2.092, P = 0.024) remained associated
with liver steatosis.
Overall, HAART medications were significantly asso-
ciated with the presence of liver steatosis, (χ2 = 11.07,
P = 0.011). Further multivariate logistic regression ana-
lysis indicated that AZT (OR = 2.11, P = 0.001) and
d4T (OR = 3.75, P = 0.01) were highly associated with
greater likelihood of liver steatosis; while NVP (OR = 0.41,
P = 0.003) was a protective factor (Table 4).
Discussion
The results of the present study, conducted in a cohort
of Chinese HIV patients with hypertriglyceridemia,
HIV/HCV co-infection and normal control, showed that
liver steatosis was significantly more common in pa-
tients with hypertriglyceridemia than that in HIV/HCV
co-infection and normal control. We found that the
prevalence of liver steatosis was 16.7% in normal con-
trol participants, which was consistent with that
reported in the general population by Fan et al. [6].
HIV/HCV co-infection may be at risk of developing
steatosis and prevalence of liver steatosis in HIV/HCV
co-infection in American and French were 69% [13] and
Table 2 Characteristics and independent risk factors of liver steatosis in Chinese HIV patients with
hypertriglyceridemia analyzed with univariate and multivariate regression analysis
Univariate analysis Mutivariate analysis
Charateristics All patients Liver steatosis Non-steatosis OR P value OR P value
Features
Age (yr) 42.9 ± 9.3 43.2 ± 9.5 42.9 ± 9.2 0.99 0.79
Male 109 (66.9%) 52 (31.9%) 57 (35.0%) 0.47 0.02
Female 54 (33.1%) 36 (22.1%) 18 (11.0%)
Smoking histroy 52 (31.9%) 27 (30.7%) 25 (33.3%) 1.13 0.72
Drinking 17 (10.4%) 12 (13.6%) 5 (6.7%) 4.615 0.03
BMI (Kg/m2)
Male patients
25-29.9 76 (69.7%) 41 (37.6%) 35 (32.1%) 0.68 0.71
≥30 13 (11.9%) 6 (5.5%) 7 (6.4%)
18.6-24.9 20 (18.4) 11 (10.1%) 9 (8.3%)
Female patients
25-29.9 36 (66.7%) 12 (22.2%) 24 (44.5%) <0.001 1.00
≥30 6 (11.1%) 2 (3.7%) 4 (7.4%)
18.6-24.9 12 (22.2%) 4 (7.4%) 8 (14.8%)
Biochemistry tests
ALT (U/L) 32.5 ± 29.3 28.8 ± 25.7 36.7 ± 32.7 1.01 0.11
AST (U/L) 31.7 ± 30.9 37.7 ± 32.1 31.3 ± 21.5 0.99 0.78
CK 115 ± 112 131 ± 186 109 ± 62 0.99 0.44
BUN (mmol/L) 4.9 ± 1.4 4.8 ± 1.0 4.9 ± 1.8 1.04 0.55
Cr (umol/L) 77.0 ± 28.5 82.3 ± 18.7 70.9 ± 35.9 0.97 0.01
Blood lipid levels
TG (mmol/L) 5.7 ± 5.2 4.7 ± 3.8 6.9 ± 6.3 1.10 0.012 1.086 0.026
TC (mmol/L) 5.5 ± 1.7 5.3 ± 1.7 5.8 ± 1.7 1.19 0.07
LDL (mmol/L) 2.8 ± 1.0 2.9 ± 0.9 2.7 ± 1.1 0.83 0.31
HDL (mmol/L) 1.3 ± 0.3 1.3 ± 0.3 1.2 ± 0.4 0.37 0.08
FPG (mmol/L) 5.7 ± 1.8 5.1 ± 1.2 6.5 ± 2.1 1.90 <0.001
Metabolic sydrome 78 (47.9%) 34 (38.6%) 44 (58.7%) 2.25 0.01 2.092 0.024
HIV infection
Time since HIV 132 ± 73 141 ± 74 117 ± 69.5 0.99 0.07
diagnosis (M)
Mos. on ART (M) 38.7 ± 25.3 37.5 ± 25.3 40.1 ± 25.5 1.00 0.39
Current CD4 316 ± 191 240 ± 141 401 ± 204 1.01 <0.001
Notes: BMI body metabolic index, ALT Alanine aminotransferase, AST Aspartate aminotransferase, CK Creatine kinase, BUN Blood urea nitrogen, Cr Serum
creatinine, TG triglyceride, TC Total cholesterol, LDL Low-density lipoprotein, HDL high-density lipoprotein, FPG Fasting plasma glucose.
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reported that prevalence in Chinese HIV/HCV co-
infected patients was 18.3%. In this study, we found the
prevalence of liver steatosis was 20.3% in the cohort of
HIV/HCV co-infection, which indicated that prevalence
in Euro-American was much higher than that in Chinese
HIV/HCV co-infected patients, and may be associated
with genetic background and HCV subtype, such as
HCV-3, in Euro-American.This Chinese cohort study found that liver steatosis
was a common condition of HIV patients with hypertri-
glyceridemia and was associated with male gender,
metabolic syndrome, higher triglyceride levels, and
higher fasting plasma glucose count as well as certain
antiretroviral medications.
We found that high triglyceride levels were associated
with liver steatosis in a Chinese HIV-infected popula-
tion with hypertriglyceridemia. HIV-infected patients
Table 4 Independent risk factors in ART regimens for liver steatosis in Chinese AIDS patients with hypertriglyceridemia
analyzed with multivariate logistic regression analysis
Mutivariate analysis
HIV medications All patients Non-steatosis Steatosis χ2 P value OR P value
AZT 73 (44.8%) 32 (36.4%) 41 (54.7%) 11.07 0.011 2.11 0.001
d4T 66 (40.5%) 39 (44.3%) 27 (36.0%) 3.75 0.01
EFV 55 (33.7%) 19 (21.6%) 36 (48.0%) 3.35 0.07
NVP 78 (47.9%) 52 (58.0%) 37 (36.0%) 0.41 0.0003
Others 17 (9.8%) 9 (10.2%) 8 (9.3%) 0.90 0.36
Notes: AZT Zidovudine, d4T Stavudine, EFV Efavirenz, NVP Nevirapine.
Table 3 Metabolic changes in HIV-infected patients with hypertriglyceridemia: comparsion with HIV/HCV co-infected
patients and normal control participants
Characteristics Control HIV/HCV co-infection HIV-infected patients with hypertriglyceridemia p value
Age (yr) 42.0 ± 4.3 42.7 ± 6.1 42.9 ± 9.3 0.873
Male (%) 14 (46.7%) 47 (68.1%) 109 (66.9%) 0.104
Female (%) 16 (53.3%) 22 (31.9%) 54 (33.1%)
Transmission route
Former plasma donators – 14 (20.3%) 41 (25.2%) –
Blood transfusion – 39 (59.5%) 9 (5.5%) –
Intravenous drug users – 7 (7.2%) 20 (12.3%) –
Sexual transmission – 9 (13.0%) 89 (54.6%) –
Unknown reason – 0 (0.0%) 4 (2.5%) –
Biochemistry tests
ALT (U/L) 18.7 ± 10.9 44.3 ± 40.3 32.5 ± 29.3 0.001
T-BIL (umol/L) 11.1 ± 3.9 12.7 ± 9.2 11.4 ± 6.2 0.129
BUN (mmol/L) 4.7 ± 1.1 4.8 ± 3.9 4.9 ± 1.4 0.836
FPG (mmol/L) 5.5 ± 1.0 5.7 ± 1.7 5.7 ± 1.8 0.755
Blood lipid levels
TG (mmol/L) 1.9 ± 1.7 1.8 ± 1.1 5.7 ± 5.2 <0.001
TC (mmol/L) 4.9 ± 0.9 3.7 ± 1.1 5.5 ± 1.7 <0.001
LDL (mmol/L) 2.8 ± 0.7 2.2 ± 0.9 2.8 ± 1.0 <0.001
HDL (mmol/L) 1.4 ± 0.7 0.9 ± 0.4 1.2 ± 0.3 <0.001
TG ≥2.26 mmol/L (%) 4 (13.3%) 12 (17.4%) 163 (100%) <0.001
1.70≤ TG≤ 2.25 mmol/L 6 (20.0%) 11 (15.9%) 0 (0%)
TC ≥6.22 mmol/L 2 (6.7%) 2 (2.9%) 45 (27.6%) <0.001
5.18≤ TC≤ 6.19 mmol/L 10 (33.3%) 2 (2.9%) 39 (23.9%)
LDL ≥4.14 mmol/L 0 (0.0%) 2 (2.9%) 14 (8.6%) 0.041
3.37≤ LDL≤ 4.14 mmol/L 7 (23.3%) 5 (7.2%) 24 (14.7%)
HDL≤ 1.04 mmol/L 7 (23.3%) 50 (72.4%) 34 (20.9%) <0.001
Metabolic sydrome 5 (16.7%) 13 (18.9%) 78 (47.9%) <0.001
Liver steatosis 5 (16.7%) 14 (20.3%) 75 (46%) <0.001
Note: Across study sites, 180 HIV-infected Patients with Hypertriglyceridemia were recruited and scheduled for ultrasound imaging. As 17 did not appear for the
screening visit, data were available for 163 participants.
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This may be due to a “two-hit” pathogenic mechanism:
(1) HIV-infected patients had high rates of lipid and
glucose abnormalities and triglyceride accumulation in
liver; (2) Those with NRTIs in ARV regimens were fur-
ther associated with lipid metabolic dysfunction,
resulting in abnormal triglyceride accumulation in the
liver. We found that some antiretroviral drugs were inde-
pendent risk factors for liver steatosis in HIV-infected,
HAART-experienced patients who had high baseline
triglyceride levels.
We also found that metabolic syndrome was a further
independent risk factor for liver steatosis in Chinese HIV-
infected patients with hypertriglyceridemia. Liver steatosis
appears to be a result of long-standing insulin-resistance
and represents a serious hepatic manifestation of meta-
bolic syndrome. After administering HAART, HIV-
infected patients have been found to have lipid metabolic
dysfunctions and lipid accumulation in the liver have
resulted in insulin-resistance [16]. HIV-infected patients
should be monitored for metabolic syndrome and liver
steatosis after administering HAART, particularly if they
have high triglyceride levels.
In this study, we found that NRTIs such as AZT and
d4T were independent risk factors for liver steatosis,
similar to results reported by Guaraldi et al. [16]. Few
HIV patients in China are on protease inhibitors (PIs),
but others have found both NRTIs and PIs to be associ-
ated with hyperlipidemia and liver steatosis [17,18].
NRTIs can inhibit mitochondrial polymerase γ and des-
troy lipid metabolic processes intracellularly, resulting
in lipid accumulation in vivo and hyperlipidemia.
HAART medications, especially thymidine analogs [19],
have promoted insulin resistance [20] and are associated
with liver steatosis in vivo.
We found that exposure to nevirapine was associated
with protection from liver steatosis. Others have reported
that nevirapine can effect favorable lipid changes [21-23],
but efavirenz did not favorably affected lipid metabolism
in vivo [23]. In a randomized clinical trial, lipid profiles
improved when efavirenz was switched to nevirapine [23].
In our study, we confirmed a protective effect of nevira-
pine vis-à-vis lipid metabolism in vivo, including protec-
tion against liver steatosis.
Our study found that NRTIs such as AZT and d4T,
and NNRTIs efavirenz were independent risk factors for
liver steatosis in Chinese HIV/AIDS individuals, and the
metabolic abnormalities may harbor a significant risk of
developing metabolic syndrome, which indicated that
regular monitoring of blood lipid levels and hepatic
steatosis with Color Doppler Ultrasound was necessary
after patients administered AZT or d4T and efavirenz.
Therapeutic and prevention strategies may be of only
limited clinical success, where avoiding the use of thesemedicines appeared to be most effective, and general
recommendations include dietary changes, lifestyle mod-
ifications and switching antiretroviral therapy (replacing
AZT or d4T with tenofovir, efavirenz with nevirapine).
Studies have reported that higher BMI is positively asso-
ciated with liver steatosis, both in the general population
and among HIV-infected patients. Higher BMI is an inde-
pendent risk factor for NAFLD [24], but we did not see
this association, which may be associated with genetic
background in study population.
We found that Individuals with liver steatosis had lower
level of triglyceride and fasting glucose, and lower preva-
lence of metabolic syndrome than those with non-
steatosis (Table 2); and we also found that proportion of
stavudine was significantly higher in non-steatosis group
than that in liver-steatosis group (Table 4). Numerous
studies have reported that stavudine had unfavorable ef-
fects of triglyceride and other metabolic disorders. Jericó
et al. [25] reported that exposure of stavudine was associ-
ated with metabolic syndrome; Podzamczer [26] and Van
et al. [27] also reported that concentration of triglyceride
continued to increase after exposure of stavudine, which
was consistent with our results.
Crum-Cianflone et al. [7] reported that liver enzyme
abnormalities was not associated with NAFLD; however,
Guaraldi et al. [16] reported that elevations in serum
ALT level were an independent risk factor in a U.S.
HIV-infected population. We did not find liver enzyme
abnormalities to be associated with liver steatosis. Liver
enzyme abnormalities were commonly seen in HIV-
infected patients [28]. We found elevations in serum
ALT level detected in patients from both liver steatosis
and non-liver steatosis groups, indicated that liver enzyme
abnormalities were associated with HIV infection and liver
metabolic abnormalities in vivo. Our data suggest that
elevations in serum liver enzyme levels were not specific
for liver steatosis.
In this cohort, we found the prevalence of liver steatosis
in HIV-infected patients with hypertriglyceridemia and
past exposure to HAART was 46%, while only 5.5% of pa-
tients had hepatomegaly detected on ultrasound imaging.
Lesi et al. [8] reported that, in African HIV-infected popu-
lation with liver steatosis, 80% of patients have been
detected hepatomegaly. Crum-Cianflone et al. [7] reported
63% of American HIV-infected population had hepato-
megaly, suggesting that genetic factors and ethnic differ-
ences should be further investigated between Chinese and
other races.
Our study limitations include: (1) the study design
was a cross-sectional and causal relationships cannot
be confirmed between risk factors and liver steatosis;
(2) the determination of fatty liver disease was based
on ultrasound imaging. Given that simple fatty liver
and fatty hepatitis cannot be differentiated in vivo, we
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liver steatosis [29].
We found that HIV-infected patients with hypertri-
glyceridemia and past HAART experience are prone to
liver steatosis. In particular, HIV-infected patients who
were using NRTIs should be screened and monitored
over time as to their cholesterol panels and other signs
of metabolic diseases.
Abbreviations
3TC: Lamivudine; ALT: Alanine aminotransferase; AST: Aspartate
aminotransferase; AZT: Zidovudine; BMI: Body metabolic index; BUN: Blood
urea nitrogen; CK: Creati0ne kinase; Cr: Serum creatinine; d4T: Stavudine;
EFV: Efavirenz; ELISA: Enzyme-linked immunosorbent assay; FPG: Fasting
plasma glucose; HAART: Highly active antiretroviral therapy; HCV: Hepatitis C
virus; HDL: High-density lipoprotein; HIV: Human immunodeficiency virus;
LDL: Low-density lipoprotein; LPV/r: Lopinavir/Ritonavir; NAFLD: Nonalcoholic
fatty liver disease; NVP: Nevirapine; TC: Total cholesterol; TCM: Traditional
Chinese medicine; TDF: Tenofovir; TG: Triglyceride.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JX collected blood samples, participated laboratory tests and drafted the
manuscript; NH collect blood samples; DY carried out statistical analysis; and
HZ designed the project. All authors read and approved the final manuscript.
Acknowledgments
We acknowledge the work of HIV health care providers for their diagnosis,
nursing and treatment of HIV/AIDS patients in Ditan Hospital. We
acknowledge the work of social workers and volunteers in Beijing Red
Ribbon who provide counseling, adherence interventions and resolving
psychosocial issues for HIV/AIDS patients.
Support for this work was provided by: (1) The Twelve-fifth Key Project The
Study of Construction of Representative areas for Prevention and Therapy of
Fatal Infectious Diseases such AIDS & Viral Hepatitis in Chaoyang District, Beijing
(2012ZX10004-904). (2) Beijing Natural Science Fund The evaluation of
association between polymorphism of leptin or adiponectin and NAFLD
complicated with AIDS (7112065).
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Received: 15 April 2013 Accepted: 9 August 2013
Published: 14 August 2013
References
1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen
JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban
population in the United States: impact of ethnicity. Hepatology 2004,
40:1387–1395.
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S:
Prevalence of and risk factors for nonalcoholic fatty liver disease: the
dionysos nutrition and liver study. Hepatology 2005, 42:44–52.
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A,
Angulo P: The natural history of nonalcoholic fatty liver disease: a
population-based cohort study. Gastroenterology 2005, 129:113–121.
4. Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to
cirrhosis. Hepatology 2006, 43(2suppl 1):99–112.
5. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis:
summary of an AASLD single topic conference. Hepatology 2003,
37:1202–1219.
6. Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY: Prevalence of and
risk factors for fatty liver in a general population of Shanghai, China.
J Hepatol 2005, 43:508–514.
7. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S,
Goodman Z, Parker R, Lifson A, Capozza T, Bavaro M, Hale B, Hames C:
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir
Immune Defic Syndr 2009, 50:464–473.8. Lesi OA, Soyebi KS, Eboh CN: Fatty liver and hyperlipidemia in a cohort of
HIV-positive Africans on highly active antiretroviral therapy. J Natl Med
Assoc 2009, 101:151–155.
9. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, Zhao D, Yu L, Goosby EP: The
Chinese free antiretroviral treatment program: challenges and responses.
AIDS 2007, 21(Suppl 8):143–148.
10. AIDS Study Group, Branch of Infectious diseases, Chinese Medical
Association: The guideline for prevention and treatment of AIDS in
Chinese. Chinese Journal of Infectious diseases 2006, 24:133–144. Chinese.
11. Chinese Medical Association: The guideline for prevention and treatment
of hyperlipidemia in Chinese adults. Chinese Journal of Cardiovascular
diseases 2007, 35:390–409. Chinese.
12. Fatty liver disease and alcohol liver disease Study Group, Branch of hepatic
diseases, Chinese Medical Association: Diagnosis and treatment guideline
for Non-alcoholic fatty liver disease. Chinese Journal of Hepatology 2006,
14:161–163. Chinese.
13. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA,
Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, Sax PE,
Graeme-Cook F, Hibberd PL: Hepatic steatosis is associated with fibrosis,
nucleoside analogue use, and hepatitis C virus genotype 3 infection in
HIV-seropositive patients. Clin Infect Dis 2006, 43:365–372.
14. Castéra L, Loko MA, Le Bail B, Coffie P, De Ledinghen V, Trimoulet P, Winnock
M, Dabis F, Neau D, Groupe D’epidémiologie Clinique du Sida en Aquitaine
(GECSA): Hepatic steatosis in HIV-HCV coinfected patients in France:
comparison with HCV monoinfected patients matched for body mass
index and HCV genotype. Aliment Pharmacol Ther 2007, 26:1489–1498.
15. Qingnian X, Hongqing S, Li L, Jiangrong W, Hongzhou L: Clinical study of
hyperlipidemia and fatty liver disease in patients receiving HAART.
Chinese Hepatology 2008, 13:372–374. Chinese.
16. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D’Amico R, Ligabue G, Fiocchi
F, Zona S, Loria P, Esposito R, Palella F: Nonalcoholic fatty liver disease in HIV-
infected patients referred to a metabolic clinic: prevalence, characteristics,
and predictors. Clin Infect Dis 2008, 47:250–257.
17. Jevtović DJ, Dragović G, Salemović D, Ranin J, Djurković-Djaković O: The
metabolic syndrome, an epidemic among HIV-infected patients on
HAART. Biomed Pharmacother 2009, 63:337–342.
18. De Luca A, Cozzi-Lepri A, Antinori A, Zaccarelli M, Bongiovanni M, Di
Giambenedetto S, Marconi P, Cicconi P, Resta F, Grisorio B, Ciardi M, Cauda
R, Monforte A: Lopinavir/ritonavir or efavirenz plus two nucleoside
analogues as first-line antiretroviral therapy: a non-randomized
comparison. Antivir Ther 2006, 11:609–618.
19. Mohammed SS, Aghdassi E, Salit IE, Avand G, Sherman M, Guindi M,
Heathcote JE, Allard JP: HIV-positive patients with nonalcoholic fatty
liver disease have a lower body mass index and are more physically
active than HIV-negative patients. J Acquir Immune Defic Syndr 2007,
45:432–438.
20. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, Chmiel JS, Visscher
BR, Margolick JB, Dobs AS: Cumulative exposure to nucleoside analogue
reverse transcriptase inhibitors is associated with insulin resistance markers
in the multicenter AIDS cohort study. AIDS 2005, 19:1375–1383.
21. Van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A,
Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P, Atlantic
Study Team: Nevirapine-containing antiretroviral therapy in HIV-1
infected patients results in an anti-atherogenic lipid profile. AIDS 2001,
15:2407–2414.
22. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B,
Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos
BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D,
Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R,
Robinson P, Wit FW, Lange JM, 2NN Study team: Comparison of first-line
antiretroviral therapy with regimens including nevirapine, efavirenz, or
both drugs, plus stavudine and lamivudine: a randomised open-label
trial, the 2NN study. Lancet 2004, 363:1253–1263.
23. Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R: Efavirenz to nevirapine
switch in HIV-1-infected patients with dyslipidemia: a randomized,
controlled study. Clin Infect Dis 2007, 45:263–266.
24. Koller T, Kollerova J, Hlavaty T, Huorka M, Payer J: Cholelithiasis and
markers of nonalcoholic fatty liver disease in patients with metabolic
risk factors. Scand J Gastroenterol 2012, 47:197–203.
25. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL,
Saballs P, López-Colomés JL, Pedro-Botet J: Metabolic syndrome among
Xiao et al. Virology Journal 2013, 10:261 Page 8 of 8
http://www.virologyj.com/content/10/1/261HIV-infected patients: prevalence, characteristics, and related factors.
Diabetes Care 2005, 28:132–137.
26. Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M,
Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E,
Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A,
Pedreira JD, Lérida A, Rubio R, del Río L, ABCDE (Abacavir vs. d4T
(stavudine) plus efavirenz) Study Team: Less lipoatrophy and better lipid
profile with abacavir as compared to stavudine: 96-week results of a
randomized study. J Acquir Immune Defic Syndr 2007, 44:139–147.
27. Van Leth F, Hall DB, Lange JM, Reiss P: Plasma lipid concentrations after
1.5 Years of exposure to nevirapine or efavirenz together with stavudine
and lamivudine. HIV Med 2006, 7:347–350.
28. Pol S, Lebray P, Vallet-Pichard A: HIV infection and hepatic enzyme
abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis
2004, 38(suppl 2):65–72.
29. Milić S, Stimac D: Nonalcoholic fatty liver disease/steatohepatitis:
epidemiology, pathogenesis, clinical presentation and treatment.
Dig Dis 2012, 30:158–162.
doi:10.1186/1743-422X-10-261
Cite this article as: Xiao et al.: Liver steatosis in Chinese HIV-infected
patients with hypertriglyceridemia: characteristics and independent risk
factors. Virology Journal 2013 10:261.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
